Indeed, immunohistochemical staining of CD8 on SMM103 subcutaneous tumor indicated that sirolimus treatment significantly increased the number of CD8+ T cells compared with saline and anti-PD-1 monotherapy (Figures 6A, B, upper). This evidence concerns the gene PDCD1 and neoplasm.